Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | CCR8 | P51685 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8737320 | 0.82 | SMN1; SMN2 (0.45) | CYP11B1CYP11B2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL8737436 | 0.82 | L3MBTL1 (0.50) | CYP11B1CYP11B2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL8736568 | 0.81 | NPC1 (0.44) | CYP11B1CYP11B2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL3388888 | 0.81 | CYP3A4 (0.46) | CYP11B1CYP11B2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL8737245 | 0.80 | HAO1 (0.51) | CYP11B1CYP11B2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL10834017 | 0.79 | HPGD (0.50) | CYP11B1CYP11B2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL25218268 | 0.79 | ALDH1A1 (0.50) | CYP11B1CYP11B2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL30474703 | 0.79 | ALDH1A1 (0.50) | CYP11B1CYP11B2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL8736781 | 0.78 | HAO1 (0.53) | SMN1; SMN2NPC1RAB9AHPGDHAO1 | |
| SCHEMBL3378744 | 0.78 | L3MBTL1 (0.53) | CYP11B1CYP11B2SMN1; SMN2HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150232455-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2015-08-20 | — | — | US | disclosed |
| US-20150203442-A1 | Anthraquinone Analogs and Methods of Making and Using Thereof | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2015-07-23 | — | — | US | disclosed |
| US-20120149706-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | DUMAS JACQUES (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149706-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | DUMAS JACQUES (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120129893-A1 | Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas | DUMAS JACQUES (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129893-A1 | Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas | DUMAS JACQUES (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120046290-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2012-02-23 | — | — | US | disclosed |
| US-20120046290-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2012-02-23 | — | — | US | disclosed |
| US-20120040977-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2007-10-18 | — | — | US | disclosed |
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203442-A1 | Anthraquinone Analogs and Methods of Making and Using Thereof | PCNA, KRAS, RECQL | CYP11B1 939/4885CYP11B2 1137/4885SMN1; SMN2 3993/4885 |
| US-20120149706-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | MAPK1, MAP3K1, MAP3K7 | CYP11B1 1501/4885CYP11B2 1782/4885SMN1; SMN2 3445/4885 |
| US-20120040977-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | CYP11B1 3519/4885CYP11B2 3975/4885SMN1; SMN2 4634/4885 |
| US-20120046290-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | MAPK1, MAP3K1, MAP3K7 | CYP11B1 1501/4885CYP11B2 1782/4885SMN1; SMN2 3445/4885 |
| US-20150232455-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | CYP11B1 2776/4885CYP11B2 3084/4885SMN1; SMN2 3721/4885 |
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BRAF, RAF1, ARAF | CYP11B1 4144/4885CYP11B2 4342/4885SMN1; SMN2 4560/4885 |
| US-20120129893-A1 | Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas | BRAF, RAF1, ARAF | CYP11B1 4144/4885CYP11B2 4342/4885SMN1; SMN2 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.